Acute headache medication overuse (MO) is common in patients with chronic migraine (CM). We evaluated safety and efficacy of onabotulinumtoxinA as preventive treatment of headache in CM patients with baseline MO (CM+MO) in a planned secondary analysis from two similarly designed, randomized, placebo-controlled, parallel, Phase III trials. Patients were randomized to treatment groups (155-195 U of onabotulinumtoxinA or placebo) using MO (patient-reported and diary-captured frequency of intake) as a stratifying variable. Of 1384 patients, 65.3
作者:Stephen D, Silberstein;Andrew M, Blumenfeld;Roger K, Cady;Ira M, Turner;Richard B, Lipton;Hans-Christoph, Diener;Sheena K, Aurora;Mai, Sirimanne;Ronald E, DeGryse;Catherine C, Turkel;David W, Dodick
来源:Journal of the neurological sciences 2013 年 331卷 1-2期